THURSDAY, Feb. 25 (HealthDay News) -- Eradication of Helicobacter pylori in the stomachs of patients with early-stage gastric lymphoma results in the remission of approximately 75 percent of them, according to a meta-analysis reported in the February issue of Clinical Gastroenterology and Hepatology.
Angelo Zullo, M.D., of the Nuovo Regina Margherita Hospital in Rome, and colleagues conducted a pooled analysis of data from 32 studies on 1,408 patients with early-stage gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach to determine remission and relapse rates following therapy to eradicate H. pylori.
The researchers found that the overall MALT lymphoma remission rate was 77.5 percent in the combined cohorts. Remission was higher in Asian than Western patients (84.1 and 73.8 percent, respectively), and higher for patients with stage I lymphoma compared to stage II lymphoma (78.4 and 55.6 percent, respectively). Remission rates also were higher among subjects without the API2-MALT1 translocation chromosomal abnormality than those with the abnormality (78 and 22.2 percent, respectively). The researchers analyzed available long-term follow-up data for 994 subjects and calculated a 7.2 percent lymphoma relapse rate over 3,253 patient-years. In subjects in which both H. pylori infection and lymphoma reoccurred (16.7 percent), re-eradication therapy effectively treated both conditions.
"H. pylori eradication is effective in treating approximately 75 percent of patients with early-stage gastric lymphoma. Long-term follow-up evaluation of these patients is needed to detect early lymphoma relapse or progression," the authors conclude.
Copyright © 2010 HealthDay. All rights reserved.
|Previous: Critical Thinking Training Is Key for Perioperative Nurses||Next: Annual Colonoscopy Helpful for High-Risk Cancer Group|
Reader comments on this article are listed below. Review our comments policy.